Comparison
Hexarelin vs Tirzepatide
Side-by-side of Hexarelin and Tirzepatide. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Hexarelin
Hexarelin peptide is a ghrelin-receptor hexapeptide. Largest acute GH pulse in the GHRP class, highest cortisol and prolactin lift, CD36 cardioprotective sign.
Tirzepatide
Tirzepatide for weight loss: dual GIP/GLP-1 agonist sold as Mounjaro and Zepbound. SURMOUNT-1 showed 22.5% mean body-weight loss at 15 mg over 72 weeks.
Effects at a glance
Hexarelin
- •Synthetic hexapeptide GHS-R1a agonist; produces the largest acute GH pulse of the synthetic GHRP class
- •Independent CD36 signaling produces cardioprotective effects in rodent ischemia models, GH-independent
- •Pronounced tachyphylaxis: GH response attenuates over 2 to 4 weeks of daily dosing
- •More cortisol and prolactin elevation than GHRP-2 or ipamorelin
- •Anecdotal protocols use 100 to 200 mcg subcutaneously 1 to 2 times daily for 2 to 4 week pulses
- •Banned by WADA under S2; advanced through phase 2 trials but never reached registration
Tirzepatide
- •Dual GIP plus GLP-1 receptor agonist with a ~5-day half-life supporting once-weekly subcutaneous dosing
- •SURMOUNT-1 reported ~22.5% mean body-weight loss at 15 mg over 72 weeks versus 2.4% on placebo
- •Lowers HbA1c by ~1.9 to 2.6 percentage points in type 2 diabetes across SURPASS trials
- •Outperformed semaglutide 1.0 mg head-to-head on weight loss and HbA1c in SURPASS-2
- •GI effects (nausea, diarrhea, vomiting) drive most discontinuations and ease with slow titration
- •Lean-mass loss observed in body-composition substudies; resistance training and protein intake mitigate this
Side-by-side
| Attribute | Hexarelin | Tirzepatide |
|---|---|---|
| Category | peptide | pharmaceutical |
| Also known as | Examorelin, EP-23905, His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2 | Mounjaro, Zepbound, LY3298176 |
| Half-life (hr) ↗ | 1 | 120 |
| Typical dose (mg) ↗ | 0.1 | 10 |
| Dosing frequency | 1-2x daily | weekly |
| Routes | subcutaneous, intranasal, intravenous | subcutaneous |
| Onset (hr) | 0.25 | 24 |
| Peak (hr) | 0.5 | 72 |
| Molecular weight | 887.04 | 4813.45 |
| Molecular formula | C47H58N12O6 | C225H348N48O68 |
| Mechanism | Hexapeptide agonist of GHS-R1a producing acute GH release with cortisol and prolactin co-elevation. Independent CD36 binding produces GH-independent cardioprotective signaling in preclinical models. | Synthetic 39-amino-acid peptide that activates both GIP and GLP-1 receptors. Potentiates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and acts on hypothalamic and brainstem satiety circuits. |
| Legal status | Not FDA approved; advanced through phase 2 trials in EU but never registered; research-use-only grey market; banned by WADA | Prescription only; FDA-approved 2022 (T2DM, Mounjaro) and 2023 (chronic weight management, Zepbound) |
| WADA status | banned | allowed |
| DEA / Rx | Not scheduled (research chemical) | Rx only (not a controlled substance) |
| Pregnancy | Insufficient data; not recommended | Not recommended; discontinue 2 months before planned pregnancy |
| CAS | 140703-51-1 | 2023788-19-2 |
| PubChem CID | 3037387 | 156588324 |
| Wikidata | Q5743550 | Q105099794 |
Safety profile
Hexarelin
Common side effects
- water retention
- vivid dreams
- head pressure or flushing
- transient lethargy
- tingling at injection site
- moderate hunger
Contraindications
- pregnancy
- active malignancy
- history of pituitary tumor
- uncontrolled diabetes
- prolactin-sensitive states
Interactions
- CJC-1295: synergistic GH release; accelerates tachyphylaxis if used continuously(minor)
- sermorelin: additive GH release via parallel GHRH and ghrelin pathways(minor)
- insulin: sustained GH can blunt insulin sensitivity over weeks(moderate)
- corticosteroids: amplify cortisol load; blunt GH response(moderate)
Tirzepatide
Common side effects
- nausea
- diarrhea
- vomiting
- constipation
- decreased appetite
- injection-site reactions
- fatigue
- abdominal pain
Contraindications
- personal or family history of medullary thyroid carcinoma
- multiple endocrine neoplasia type 2
- pregnancy
- history of pancreatitis (use caution)
- severe gastroparesis
Interactions
- insulin: additive hypoglycemia risk; insulin dose typically reduced(major)
- sulfonylureas (glipizide, glyburide): hypoglycemia risk, sulfonylurea dose often reduced(major)
- oral medications (general): delayed gastric emptying can alter absorption kinetics(moderate)
- oral contraceptives: reduced exposure after first dose; backup contraception recommended for 4 weeks after initiation and each dose escalation(moderate)
- warfarin: monitor INR due to altered absorption(moderate)
Which Should You Take?
Tirzepatide comes out ahead for most readers on the criteria we weight: 3 catalogued goals, prescription-only, with a Tier-A outcome catalogued. Hexarelin is the right call when one of the conditionals below applies.
- → If your priority is growth-hormone axis, pick Hexarelin.
- → If your priority is post-training recovery, pick Hexarelin.
- → If your priority is metabolic health and glucose control, pick Tirzepatide.
- → If your priority is fat loss, pick Tirzepatide.
Edge case: Half-lives differ materially (Hexarelin ~1 hr vs Tirzepatide ~120 hr). Tirzepatide reaches steady state faster; Hexarelin is easier to dial in if tolerability is uncertain.
Default choice: Tirzepatide. Wider use case, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Hexarelin only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Hexarelin and Tirzepatide?
Hexarelin and Tirzepatide differ in category (peptide vs pharmaceutical), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Hexarelin or Tirzepatide?
Hexarelin half-life is 1 hours; Tirzepatide half-life is 120 hours.
Can you stack Hexarelin with Tirzepatide?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper